To test whether or not the association between inflammation and pancreatic ductal adenocarcinoma (PC) is facilitated by host susceptibility, specifically by genetic polymorphisms in inflammation-related genes. Summary Background Data: Inflammation has been linked to PC. Reports have cited an increased expression of proinflammatory mediators, such as NF-κB and COX, in PC but not in normal adjacent tissue, suggesting a possible role in carcinogenesis. We sought to further understand the role that genetic variants in the NF-κB inflammatory pathway play in the development and progression of PC. Methods: We genotyped 1536 tag single nucleotide polymorphisms (SNPs) in 102 candidate genes of multiple inflammatory pathways in 1308 white patients with PC who were divided into 3 groups on the basis of the extent of disease: resected for cure (n = 400), locally advanced/unresected (n = 443), and metastatic (n = 465). Survival analysis was performed using Kaplan-Meier curves and Cox proportional hazards regression models. Statistical significance was set at less than 0.001 to control for multiple testing. Results: Median age was 67 (28.0-91.0) years, and 57% were men. Median survival for each of the 3 groups (resected, locally advanced, and metastatic) was 23.7, 9.4, and 6.6 months, respectively (P < 0.0001). In the resected group, carriers of a minor allele for either rs3824872 (MAPK8IP1) or rs8064821 (SOCS3) were associated with a 10-and 6-month survival advantage compared with noncarriers in patients with resected disease, with an additional 2-year survival if both minor alleles were present. With locally advanced disease, SNP rs1124736 (IGF1R) was associated with improved survival if they had a copy of the G allele, hazard ratio of 0.57 (95% confidence interval: 0.42-0.77); P = 0.0002. In addition, 4 SNPs in patients with metastatic disease were found to be associated with worse survival and 2 associated with improved overall survival, but the differences in survival were deemed not clinically significant. Conclusions: SNPs in the inflammatory pathway genes MAPK8IP1 and SOCS3 were associated with increased overall survival in patients undergoing From the
T he lethality of pancreatic ductal adenocarcinoma (PC) is remarkable. In the period from 1999 to 2006, the 5-year relative survival in the United States was only 5.4%. 1 Operative resection is the single most important treatment modality that has a positive impact on survival. The overall 5-year survival after resection improves to approximately 20% 2,3 ; however, in stage IA disease, the 5-year overall survival can be as high as 32%. 4 Other clinicopathological features that seem to have a positive impact on survival are the lack of lymph node metastases, a negative resection margin (R0), lack of need for blood transfusion, postoperative chemoradiation therapy, and the deoxyribonucleic acid content of the tumor. [5] [6] [7] [8] [9] [10] Furthermore, predisposing disease processes, such as chronic pancreatitis, 11 and environmental factors, such as smoking, 12 increase the risk of PC. A pathway shared between these risk factors is inflammation.
The genetic basis of the association between inflammation and PC is of considerable interest. Although clinicopathological factors allow us to relay favorable or unfavorable prognostic information to a patient with PC, they are imperfect in identifying with certainty the individuals who will develop PC. An ideal marker would be a germline marker, because it is measurable, not subject to change, and robust in storage and technical conditions. There is increasing interest in identifying a genetic marker to serve as a prognostic indicator for patients with PC. Most reports have focused on response to drug treatment. 13 In an effort to identify such a marker, we evaluated single nucleotide polymorphisms (SNPs) in candidate genes in the inflammatory pathway genes to assess their impact on survival in surgically treated patients with PC. Our hypothesis was that SNPs in certain genes in the inflammation pathway would affect survival after operative resection of adenocarcinoma in patients with PC.
to whites only, of whom 98% of the population was comprised (N = 1308).
The patients were divided into 3 groups on the basis of review of the medical record: "resected," if they had an operative procedure to remove a portion or all of the pancreas as potentially curative treatment of pancreatic cancer; "locally advanced," if they were not an operative candidate or had unresectable disease but did not have metastatic disease (American Joint Committee on Cancer, 6th Edition, Stage III Disease); and "metastatic," if they had evidence on imaging of distant disease (American Joint Committee on Cancer, 6th Edition, Stage IV Disease).
Candidate Gene and SNP Selection
Candidate genes were selected using a combination of literature review and bioinformatics to identify previously reported genes involved in the pathogenesis of PC that participate in the inflammatory pathways involving NF-κB. A list of preselected genes was used to generate a list of more than 10,000 candidate genes using bioinformatic tools of Ingenuity Systems (Redwood, CA) and MetaCore from GeneGo, Inc (St Joseph, MI) on the basis of pathway analysis, and understanding the PC disease process from this list, 102 genes were selected for genotyping.
To create a panel of linkage disequilibrium tag SNPs for the 102 candidate genes, we used genotypes that were made available from the genome-wide genotyping project, HapMap Phase II, 16 and 2 gene-resequencing initiatives: SeattleSNPs 17 and National Institute of Environmental Health Sciences SNPs. 18 To determine the HapMap SNPs for each of the candidate genes, we picked SNPs 5 kb upstream and downstream of each gene. Our gene and SNP coordinates were based on RefSeq release 29 (NCBI build 36) and dbSNP build 129 (http://HapMap.ncbi.nlm.nih.gov/). If the gene was resequenced in SeattleSNPs or National Institute of Environmental Health Sciences SNPs, we used genotypes from those sources as well. At the time we picked these SNPs, National Institute of Environmental Health Sciences SNPs had resequenced 4 of our candidate genes, and the SeattleSNPs had resequenced 26.
To pick linkage disequilibrium tag SNPs, we ran linkage disequilibriumSelect 19 on each gene for each genotype source (HapMap, Seattle, National Institute of Environmental Health Sciences) for the white samples in those public sources. We used an r 2 of 0.9 to select tagSNPs with high linkage disequilibrium and a minor allele frequency cutoff of 0.05. To determine the best source of genotypes for each gene where a gene had been resequenced, we selected the source with the greater number of linkage disequilibrium bins for the white samples after bins were removed and that did not have a tag SNP with an assay score of 0.4 or more. If each source (eg, HapMap, SeattleSNPs) had the same number of bins, we used HapMap as the best source because of its greater number of samples (60 unrelated white samples). If there were more than 10 SNPs in a linkage disequilibrium bin, 2 tag SNPs were selected from that bin, and if there were more than 30 SNPs in a bin, 3 tag SNPs were selected from that bin. HapMap was chosen as the best source for 79 genes, SeattleSNPs for 19 genes, and National Institute of Environmental Health Sciences SNPs for 3 genes. After selecting a total of 1536 linkage disequilibrium-based tag SNPs 19 and prioritizing for inclusion of nonsynonymous-tag SNPs, genotyping occurred in 2 phases in the patients described previously, genotyping 768 SNPs each time for a total of 1536 SNPs genotyped.
Genotyping
High-throughput genotyping was performed using Bead-Lab technology from Illumina, Inc (San Diego, CA) at the Mayo Clinic's Advanced Genomics Technology Center Genotyping Shared Resource. 20 The quality control results have been reported elsewhere. 14, 15 Each plate had trios from the Centre d'Etude du Polymorphisme Humain in duplicates and 2 random duplicates of subject samples per plate.
Phase 1
During the first phase of genotyping, 61 genes were genotyped on a 1536 SNP panel using Illumina GoldenGate (San Diego, CA) chemistry; of these 1536 SNPs, 768 were in the genes of interest herein. Coverage of the SNPs of any given gene was greater than 90% in 51 (83.6%) of the 61 genes. The 10 (16.4%) remaining genes had 50% to 85% SNPs, largely because tag SNPs were not used if they were within 60 base pairs, within areas of insertions or deletions, had an Illumina (San Diego, CA) design score of less than 0.6 (see later), or were obtained from complementary deoxyribonucleic acid sequences.
Phase 2
In the second phase of genotyping, 41 genes were genotyped on a 1536 SNP panel using Illumina GoldenGate (San Diego, CA) chemistry; of those 1536 SNPs, 768 were in the genes of interest herein. Coverage of the SNPs of any given gene was more than 90% in 35 (85.4%) of the 41 genes. The 6 (14.6%) remaining genes had 35% to 89% SNP coverage for the same reasons as described previously.
Overall Quality Control
SNPs were considered to be genotyped successfully if the call rate was more than 95% for each subject; 7 cases and 6 controls fell below this threshold for a genotyping pass rate of 99.99%. If an SNP deviated from Hardy Weinberg Equilibrium (P < 0.00001), the SNP was excluded from further analysis. Of the 1536 SNPs that were genotyped, the following quality control concerns were identified: 30 SNPs were monomorphic, the lab failed 110 SNPs, and 12 SNPs had Hardy Weinberg Equilibrium (P < 0.00001). All duplicates had concordance of more than 90%. Only 1 subject sample failed genotyping and as such was not included in the Kaplan-Meier or Cox regression survival analyses.
Operative and Pathological Data Collection
The medical record was abstracted by a surgeon (KRL). Abstracted data included operative procedure, pathological resection margin (R status), lymph node status (positive vs negative), perioperative mortality, date of death, and treatment with radiation and/or chemotherapy. In addition, operative details, such as vein resection and pathological assessments of neural and vascular invasion, were included. For descriptive purposes, the presence of extensive fibrosis and inflammation was recorded if it was mentioned in the pathology report.
Statistical Analysis
The association between genotyped SNPs using the dominant model (0 = noncarrier, 1 = carrier of 1 or more copies of the minor allele) and survival was of primary interest. Kaplan-Meier curves were used to visualize survival with estimated median survival presented in the tables. Multivariable Cox proportional hazards regression analysis was used to further investigate these associations between SNP and survival. Models were adjusted for age, sex, stage of disease, and categorized body mass index (<30 not obese or ≥30 obese). In addition, the following surgical variables were also included as adjusters in the analysis of the resected patients: margin status (R0-no neoplastic cells at the surgical margin, R1-margin positive microscopically for neoplastic cells, R2-margin positive grossly for neoplastic cells), grade, lymph node status, and maximum tumor dimension. The SNP-SNP interaction analyses using a dominant model coding for the minor allele (ie, carrier status yes/no) were investigated for SNPs, with a P < 0.001.
RESULTS

Clinical Characteristics
There were 1328 patients eligible for inclusion and we limited the current analysis to 1308 whites. Patients were divided into 3 groups: resected PC (n = 400), locally advanced and unresected disease (n = 443), and those with metastatic disease (465). Overall, 57.4% were men, and the median overall age at initial diagnosis of PC was 67 years (range, 28-91 years). Overall, there were 83 patients with a reported family history of PC: 28 (7%) in the resected group, 24 (5.4%) in the locally advanced group, and 31 (6.7%) in the metastatic group. Fourteen patients (6, 4, and 4 in each group, respectively) reported a history of chronic pancreatitis diagnosed 3 years or more prior to the diagnosis of PC, and 150 patients (68, 42, and 40 in each group, respectively) reported a history of chronic pancreatitis diagnosed within a year of the diagnosis of PC.
Of the 400 patients with resected disease, 16.7% were stage I and 83.3% were stage II ( Table 1 ). In the locally advanced group, 158 (35.7%) were stage II and the remaining 285 (64.3%) were stage III. The types of resections in the resected group were pancreatoduodenectomy in 322 (80.5%), distal pancreatectomy in 67 (16.8%), and total pancreatectomy in 11 (2.8%). The majority of patients (83%) undergoing resection had an R0 resection, defined as no neoplastic cells at the margins of the operative specimen.
Chemoradiotherapy
The vast majority of all patients underwent chemotherapy, 90.2%, with no significant difference observed across stages (P = 0.1374); chemotherapy was delivered to 92.6%, 88.5%, and 88.6%, in the resected, locally advanced, and metastatic groups, respectively. Gemcitabine was the chemotherapy agent used most frequently in all groups: 79.8% for patients with resected disease, 71.7% in locally advanced, and 87.0% in patients with metastatic disease (P = 0.0001). The frequency of radiotherapy in the resected, locally advanced, and metastatic groups was 66.3%, 47.9%, and 7.3%, P < 0.0001, respectively, with an overall frequency of 39.1% for all patients.
Overall Survival
The median survival from the time of diagnosis for patients in the resected group was 23.7 (20.4-25.9) months, with a 5-year survival rate of 20.3% versus 9.4 (8.7-10.3) months in the locally advanced group and 6.6 (6.1-7.3) months in patients diagnosed with metastatic disease (Table 1 ).
Resected Disease
Genetic Predictors of Improved Overall Survival
We evaluated 1536 tag SNPs in 102 candidate genes and identified 3 genes harboring SNPs with a significant clinical impact on overall survival in the resected group (Table 2 ). In the MAPK8IP1 gene, SNP rs3824872 was associated with an approximate 6-month median survival advantage (27.5 vs 21.5 months) in patients with at least 1 copy of the minor allele (A) (hazard ratio: 0.66, 95% confidence interval: 0.52-0.84, P = 0.0009) (Fig. 1) . The other clinically interesting SNP in the resected group, SOCS3 gene SNP rs8064821, was associated with a hazard ratio of 0.65 (95% confidence interval: 0.49-0.87, P = 0.0042), and a median survival advantage of approximately 10 months (31.4 vs 21.5 months) between carriers of the minor allele (C) and homozygote major allele carriers (Fig. 2) . For patients who carry a copy of a minor alleles (C/C) at both rs8064821 (SOCS3) and rs3824872 (MAPK8IP1), the observed median overall survival was 3.8 years compared with a median of 1.7 years for noncarriers (Table 3 ) (hazard ratio: 0.372, 95% confidence interval: 0.23, 0.60, P < 0.0001) in the resected group.
Genetic Predictors of Poor Overall Survival
In the resected group, 1 gene, PTGFRN, contained 2 SNPs that predicted worse overall survival. If a patient carried minor alleles rs6688746 and rs11583422 in the PTGFRN gene, there was an observed decrease in overall survival of 8 and 9 months, respectively, with corresponding hazard ratios of 2.53 (95% confidence interval: 1.50-4.26, P = 0.0005) and 2.76 (95% confidence interval: 1.53-4.97, P = 0.0007) ( Table 2 and Figs. 3 and 4 ).
Impact of Chemotherapy and Radiation--Resected Group
Although survival was improved for carriers of the minor alleles of SNPs rs3824872 (MAPK8IP1) and SNP rs8064821 (SOCS3) in resected patients, this did not seem to be driven by the delivery of chemotherapy or radiation therapy as survival was highest among the group of patients with the minor allele in each group evaluated (chemotherapy, yes or no and radiation therapy, yes or no) (Supplemental Table 1 , available at http://links.lww.com/SLA/A331). The overall survival was highest among patients who carried at least 1 copy of the minor alleles and who were treated with chemoradiation; however, even if a patient was not treated with chemoradiation therapy, the survival was higher among those who were carriers of the minor allele for each SNP.
Similarly, patients who were carriers of the minor alleles associated with poor survival (rs6688746 and rs11583422 in the PT-GFRN gene) observed worse overall survival even when treated with chemotherapy and radiation therapy when compared with those who were homozygote major allele carriers (Supplemental Table 1 , available at http://links.lww.com/SLA/A331).
Locally Advanced Disease Genetic Predictors of Improved Overall Survival
In locally advanced disease, rs11247367 in the IGFIR gene was associated with improved survival if a patient carried a copy of the G allele, hazard ratio: 0.57 (95% confidence interval: 0.42-0.77), P = 0.0002. The median overall survival of carriers of the minor allele was 2 months longer than patients who were major allele carriers (11.3 vs 9.0 months). If a patient carried 2 copies of the minor allele (G/G), there was an observed worse survival than carriers of only 1 copy of the minor allele or those who were homozygote carriers of the major allele (A). This SNP, however, has a low minor allele frequency of only 7% (Table 2 ).
Genetic Predictors of Poor Overall Survival
In the NFKBIA gene, SNP rs7157810 and rs150327044 in NOS3 were associated with worse overall survival by 1 to 2 months if patients were carriers of 1 or more copies of the variant (C) allele. The minor allele frequencies were 20.2% and 32.8% ( Table 2) . 
DISCUSSION
In this candidate inflammation pathway gene study, SNPs in inflammatory-related genes of the NF-κB pathway were genotyped to assess their impact on survival in patients with PC. We have identified 4 potential markers that may be used to predict overall survival after resection of PC. The observed improvement in overall survival among these SNPs was from 6 to 10 months, an observation that was consistent across treatment with radiation and/or chemotherapy. The most interesting of the SNPs, rs8064821 in the SOCS3 gene, had an observed 10-month increase in overall survival among the resected patients. This association was observed whether patients did or did not receive radiation or chemotherapy in the resected group. Patients who carried the minor alleles of both rs3824872 (MAPK8IP1) and rs8064821 (SOCS3) had an observed doubling of their overall survival from a median of 1.7 years to a median survival of up to 3.8 years.
Resected Group
No prior studies have reported on the role of variants in MAPK8IP1 and SOCS3 as a possible predictor of overall survival. However, a recent report suggested a role for SOCS3 in the progression of precursor lesions of the pancreas, pancreatic intraepithelial neoplasm to PC via the IL6-signaling pathway in a mouse model. 21 They found that SOCS3 and KRAS mutations were associated with pancreatic intraepithelial neoplasm progression to PC. The authors discussed that STAT3 is important in that it regulates KRASdependent apoptosis and leads to tumor growth via a modulation of the stroma and the immune system. SOCS3 normally serves to inhibit STAT3; however, if a homozygous deletion occurs in the SOCS3 gene, then its normally inhibitory function is reversed leading to increased levels of SOCS3 and an observed progression to PC is observed. STAT3 induction is achieved by phosphorylation of STAT3 via interleukin 1L6. In a previously reported study, IL6 levels of more than 5.2 pg/mL in the serum were associated with worse overall survival in patients with PC. 22 This observation may be due to the contribution of IL6 to cachexia and hypermetabolism 23 in patients with PC or perhaps by contributing to the progression of disease. Although genetic variants in STAT3 were not associated with improved overall survival using our cutoff values, with improved survival (P = 0.004-0.008), 3 SNPS were found to interact with SOCS3 SNP rs8064821 and were found to have improved overall survival if the subject carried copies of both the variant SOCS3 SNP and the variant STAT3 SNPs, suggesting a potentially biological interaction. Our study, however, was not powered for this analysis and follow-up is needed.
In addition to genetic variants in SOCS3, SNP rs3824872 in the MAPK8IP1 was associated with improved overall survival. The MAPK8IP1 gene is thought to play an important role in the development of diabetes. MAPK8IP1 is a transcript of the insulin-brain-1 gene, which is a deoxyribonucleic acid-binding transactivator of the glucose transporter. 24 Insulin-brain-1 is predominately found in pan-creatic islet β-cell protein related to JIP-1, which is highly expressed in pancreatic β-cells where it functions as a transactivator of the glucose transporter gene. 25 The exact role of MAPK8IP1 in PC is unclear.
Both the minor alleles identified in the SOCS3 and MAPK8IP1 genes are located in the promotor region of the gene and have a medium risk of a functional effect as predicted by FastSNP. 26 Further exploration using the Alibaba2.1 net-based transcription factor-binding site search tool (http://www.gene-regulation.com/ pub/databases.html) 27, 28 predicted in silico that the presence of the minor allele rs8064821 in the SOCS3 led to an introduction of a new transcription-binding site for the transcription factor nuclear factor 1. There was no predicted functional effect for the minor allele, rs3824872, in the MAPK8IP1 gene. The SNPs in the PTFGRN genes are intronic with no predicted function effect.
Locally Advanced Group
In the locally advanced tumor group, we identified 3 genes with genetic variants that were associated with changes in overall survival. The first IGF1R was associated with improved survival whereas the other 2 NFKB1A and NOS3 were associated with worse OS. The clinical significance of the differences in the latter 2 genes was small. In the IGF1R gene, SNP rs11247367 was associated with improved overall survival by 2 months, with improved survival modified by chemoradiation therapy. Dong et al 29 recently reported on genetic variants in insulin-like growth factor pathways and identified 2 SNPs in the IGF1R gene with improved overall survival and hazard ratio, similar to our findings with hazard ratio ranging from 0.60 to 0.87, depending on genotype. IGF1R overexpression inhibits apoptosis of PC cells and allows for motility in the host via the PI3K/AKT/mTOR and RAS/MAPK/ERK pathways. 30, 31 Similar observations seen between our studies warrant further investigation to assess the functional implications of this intronic SNP as there were no in silico functional effect.
Metastatic Group
Six SNPs in 4 genes were associated with survival, 2 with improved survival and 4 with worse survival; however, the survival differences on average were only 2 months. These differences lack clinical significance as their clinical impact would be minor. The most important of these SNPs, rs2326173 of the RIPK1 gene had a predicted loss of 3 transcription factor-binding sites, IRF9, LMOD1, IRF8, in silico. 27 Recently, Chae et al 32 published that the GA+AA genotype of the RIPK1 rs2272990 was associated with a worse disease-free and disease-specific survival in colorectal cancer after complete resection. The minor allele of RIPK1 rs2326173 in our study was associated with worse overall survival in PC with metastatic disease.
The obvious strength of this study is the large sample of patients with surgically resected PC. Results were rigidly adjusted for known factors that portend a poor outcome of patients with PC (eg, lymph node status, tumor size, stage). The ability to clinically predict survival on the basis of genotype after surgical resection would be Copyright © 2013 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. helpful as we may be able to determine who would benefit from either conservative therapy or more aggressive therapeutic strategies such as surgery with chemoradiation therapy.
An important limitation of this study is that the results have yet to be validated in an independent data set. Because of the relatively low frequency of patients with surgically treated PC (15%-20% of all patients are diagnosed with the disease), additional time is required to collect an adequate validation sample. This work is presently underway. Another important limitation is that our study was not powered to address the impact of radiation and chemotherapy in the cohorts; however, the median survival of carriers of the minor alleles in the resected group did not seem to be driven solely by radiation and chemotherapy as patients had higher median survival whether or not they were treated with radiation and chemotherapy.
CONCLUSIONS
Variants in genes in the inflammation-related pathway may determine clinical prognosis and aid in treatment planning for patients who are candidates of resection with PC. Prognostic information for patients with locally advanced and metastatic disease may potentially also be determined by genotype.
